Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01687127
Other study ID # H11-03009
Secondary ID CIHR Application
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date December 31, 2026

Study information

Verified date August 2023
Source University of British Columbia
Contact Yvonne Lamers, PhD
Phone 604-827-1776
Email yvonne.lamers@ubc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Periconceptional supplementation with folic acid - the synthetic form of the B-vitamin folate - reduces the occurrence of adverse pregnancy outcomes such as spina bifida. The underlying biochemical mechanisms for how folic acid affects health outcomes however are unknown. The naturally occurring form 5-methyltetrahydrofolate (5-MTHF) is now available and discussed as an adequate substitute to folic acid. This study aims to determine the effect of folic acid compared to 5-MTHF on cellular mechanisms. Stable isotope tracer protocols will be used that allow determining the effect of folic acid on the dynamics of metabolic pathways in the human body. Hypothesis: Supplementation with high-dose folic acid alters the turnover rate of folate dependent pathways in healthy humans; but 5-MTHF does not. Genetic variations in a key enzyme of the folate metabolism will aggravate the effect of folic acid on the metabolic pathways.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 25
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria: - Generally healthy - Body mass index of between 19-24 kg/m2 - Normal folate, vitamin B12, and B6 status Exclusion Criteria: - Unable to swallow tablets - Unable to receive intravenous catheters - Use of vitamin supplements, amino acid or protein supplements for more than six months before study participation - Chronic consumption of a high-protein diet (e.g. Atkins Diet) - Medical conditions such as diabetes, asthma, cancer, cardiovascular disease, a history of neural tube defect (such as spina bifida) affected pregnancy, have had gastrointestinal surgery, abnormal kidney, thyroid function, or psychiatric illness, or any other chronic disease - Pregnancy or lactation - Smoking, use of recreational drugs, and/or consumption of more than one alcohol drink per day or more than seven per week. - Use of long-term prescription medication such as hormonal contraceptives, antidepressants, anticonvulsants, anticoagulants, or other chronic medication - Blood donation in the last three months prior to study start - Unable to provide informed consent, or unable to read and write English - Low compliance to intervention as determined by early steady-state or reduction in blood folate concentrations

Study Design


Related Conditions & MeSH terms

  • One-carbon Metabolism in Healthy Individuals

Intervention

Dietary Supplement:
Folic acid
Supplement
5-methyltetrahydrofolate, calcium salt
Supplement

Locations

Country Name City State
Canada Children's and Women's Health Centre of BC (incl. Sunny Hill), Child and Family Research Institute Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plateau enrichment of infused amino acid tracers and related metabolites to quantify turnover rates of folate dependent pathways 24 weeks